FinscoFinsco

Cullinan Therapeutics (US.CGEM)

Capital Allocation Audit · Period: 2018 – 2026

$Open the interactive terminal to run `audit` and explore all dimensions.→

Key Metrics

US.CGEM · YoY: 2026 Q1 vs 2025 Q1

MetricValueYoY
FCF Conversion100.0%→
ROE-13.6%↓
Cash Conversion-→
D/E Ratio0.01↓
Gross Margin-→
US.CGEM (Cullinan Therapeutics) | YoY: 2026 Q1 vs 2025 Q1


Metric            Value  YoY
----------------------------
FCF Conversion   100.0%    →
ROE              -13.6%    ↓
Cash Conversion       -    →
D/E Ratio          0.01    ↓
Gross Margin          -    →
Key Metrics
US.CGEM (Cullinan Therapeutics) | YoY: 2026 Q1 vs 2025 Q1
Metric Value YoY
----------------------------
FCF Conversion 100.0% →
ROE -13.6% ↓
Cash Conversion - →
D/E Ratio 0.01 ↓
Gross Margin - →

Audit Dimensions

Capital FlowReturnsEarning QualityDebt DisciplineMoat

Unlimited Companies

AppleMicrosoftAlphabet-AAmazonNVIDIAMeta PlatformsTeslaBerkshire Hathaway-BJPMorganVisaJohnson & JohnsonWalmartProcter & GambleExxon MobilUnitedHealthHome DepotMasterCardPfizerAbbVieCoca-ColaPepsiCoCostcoNetflixAdvanced Micro DevicesSalesforceDisneyNikeBoeingCaterpillarGoldman SachsAlibabaPDD HoldingsJD.comNIO IncLi AutoBaiduTaiwan SemiconductorASML HoldingEli Lilly and CoBroadcomCiscoOracleIntelAT&TVerizonMerck & CoTexas InstrumentsUnited Parcel ServiceRTX CorpLowe's Companies